Potential Effects of Metformin on Aging and Age Related Conditions Small Scale Clinical Studies and Secondary Analysis of Controlled Clinical Studies (R01) | Apply Online

FAQs: NIH PA-12-271 - Potential Effects of Metformin on Aging and Age Related Conditions (R01)

What is PA-12-271?

PA-12-271 is an NIH funding opportunity announcement (FOA) titled "Potential Effects of Metformin on Aging and Age Related Conditions: Small Scale Clinical Studies and Secondary Analysis of Controlled Clinical Studies (R01)." It was created to support research examining metformin's potential effects on biological pathways related to aging and age-related conditions, beyond its established use as an antihyperglycemic drug.

What is the main goal of this funding opportunity?

The FOA aims to encourage translational aging research that can clarify whether metformin has realistic potential to slow harmful age-related changes, reduce the risk or progression of age-associated diseases, and/or extend healthy human lifespan (healthspan).

Why is metformin being studied in the context of aging?

The announcement is based on growing clinical evidence across different patient groups suggesting metformin may influence biological pathways tied to aging and age-related conditions. NIH sought studies that evaluate these potential effects in humans using physiologic measures, biomarkers, and analyses of controlled clinical datasets.

What grant mechanism is used for this opportunity?

This FOA uses the NIH R01 funding instrument.

What kinds of projects does PA-12-271 support?

The FOA targets two broad categories of projects: (1) small-scale physiologic studies in humans that directly measure metformin's effects on human physiology, cellular processes, and aging-relevant biomarkers; and (2) secondary analyses of existing controlled clinical intervention studies, including analyses using previously collected data and/or stored biospecimens.

What are "small-scale physiologic studies" in this FOA?

These are focused clinical studies in humans designed to generate strong mechanistic and translational evidence about how metformin affects aging-relevant biology. They are not intended to be large, definitive outcomes trials; instead, they emphasize measurable near-term effects such as functional measures, metabolic and inflammatory profiles, stress-response pathways, and other biological signatures relevant to healthier aging trajectories.

Does this FOA fund large outcomes trials designed to be definitive?

Based on the FOA description provided, the supported clinical research is not positioned as massive, definitive outcomes trials. The emphasis is on small-scale studies that produce mechanistic and translational insights.

What is meant by "secondary analysis" of controlled clinical studies?

Secondary analysis refers to re-analyzing data from existing controlled clinical intervention studies and/or analyzing stored biospecimens collected previously. The intent is to leverage completed trials or intervention studies to answer new questions about aging-related outcomes, potentially saving time and resources.

Can applicants propose analyses using stored biospecimens?

Yes. The FOA explicitly includes secondary analysis using previously collected data and/or stored biospecimens from controlled clinical intervention studies.

What types of outcomes or measurements are emphasized?

The FOA emphasizes outcomes that can link metformin exposure to aging-related biology, including functional measures, metabolic profiles, inflammatory profiles, stress-response pathways, and other biological signatures relevant to aging and age-related conditions.

What is meant by "translational aging research" in this context?

In this FOA, translational aging research refers to hypothesis-driven studies in humans (or using human clinical datasets and biospecimens) that help bridge mechanistic understanding and real-world clinical relevance, clarifying whether metformin engages aging-related mechanisms in ways that could meaningfully affect healthspan.

Does the FOA focus on identifying who might benefit most from metformin?

Yes. A central emphasis is understanding metformin's clinical translational potential in aging, including identifying which populations might benefit most and recognizing that effects may vary by age, baseline metabolic status, comorbidities, genetic background, or other clinical characteristics.

Is the FOA interested in molecular targets beyond metformin itself?

Yes. The FOA highlights learning more about metformin's physiologic and cellular effects in humans in ways that can point to novel molecular targets. Even if metformin is not the ultimate intervention for healthy aging, the pathways it influences could reveal new therapeutic strategies or drug targets relevant to delaying age-related decline.

Which research areas does this FOA align with administratively?

Administratively, the FOA is associated with CFDA numbers 93.866 (Aging Research) and 93.393 (Cancer Cause and Prevention Research), reflecting interest in general aging biology and disease-related outcomes that intersect with aging.

Is cost sharing or matching required?

No. The opportunity did not require cost sharing or matching.

When was this funding opportunity posted?

The FOA was posted on August 24, 2012.

What was the closing date for applications?

The closing date was January 7, 2016.

Is the FOA still active?

No. It was archived on February 7, 2016.

Who was eligible to apply?

The eligible applicant pool was broad and included many types of U.S. organizations and governments (including state, county, city/township, and special districts), public and private institutions of higher education, nonprofit organizations (with and without 501(c)(3) status), small businesses and other for-profit organizations, independent school districts, public housing authorities, and a wide range of tribal entities and regional organizations.

Were for-profit organizations eligible?

Yes. The eligibility description includes small businesses and other for-profit organizations.

Were nonprofit organizations eligible even without 501(c)(3) status?

Yes. The eligible applicant types explicitly included nonprofit organizations with and without 501(c)(3) status.

Could foreign (non-U.S.) institutions apply?

Yes. The FOA explicitly allowed non-U.S. (foreign) institutions to apply.

Are foreign components allowed under this FOA?

Yes. The FOA permitted foreign components under NIH policy and allowed non-domestic components of U.S. organizations, indicating openness to international collaboration and globally sourced datasets and biospecimen resources relevant to metformin and aging research.

What is the practical "takeaway" of what NIH wanted to fund?

NIH support under this FOA was aimed at carefully designed, hypothesis-driven studies that either (1) test metformin's near-term, measurable effects on human aging-related biology, or (2) extract new aging-relevant insights from existing controlled intervention studies using previously collected data and/or biospecimens.

What outcomes or benefits were expected from funded projects?

The expected payoff was clearer evidence about whether metformin meaningfully engages aging-related mechanisms in humans, which groups might see the most benefit, and what mechanistic clues could guide future interventions aimed at extending healthspan.